

Nicholas P Van Der Meulen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/515568/publications.pdf>

Version: 2024-02-01

69
papers

2,178
citations

186265

28
h-index

233421

45
g-index

71
all docs

71
docs citations

71
times ranked

1408
citing authors

#	ARTICLE	IF	CITATIONS
1	Promising Prospects for ⁴⁴ Sc-/ ⁴⁷ Sc-Based Theragnostics: Application of ⁴⁷ Sc for Radionuclide Tumor Therapy in Mice. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1658-1664.	5.0	163
2	⁴⁴ Sc-PSMA-617 for radiotheragnostics in tandem with ¹⁷⁷ Lu-PSMA-617” preclinical investigations in comparison with ⁶⁸ Ga-PSMA-11 and ⁶⁸ Ga-PSMA-617. <i>EJNMMI Research</i> , 2017, 7, 9.	2.5	140
3	Scandium and terbium radionuclides for radiotheragnostics: current state of development towards clinical application. <i>British Journal of Radiology</i> , 2018, 91, 20180074.	2.2	120
4	Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1919-1930.	6.4	109
5	Cyclotron production of ⁴⁴ Sc: From bench to bedside. <i>Nuclear Medicine and Biology</i> , 2015, 42, 745-751.	0.6	91
6	Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 1, 5.	3.9	72
7	Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with ¹⁵² Tb-DOTATOC. <i>Dalton Transactions</i> , 2017, 46, 14638-14646.	3.3	61
8	Measurement of ⁴³ Sc and ⁴⁴ Sc production cross-section with an 18 MeV medical PET cyclotron. <i>Applied Radiation and Isotopes</i> , 2017, 129, 96-102.	1.5	61
9	Future prospects for SPECT imaging using the radiolanthanide terbium-155 ” production and preclinical evaluation in tumor-bearing mice. <i>Nuclear Medicine and Biology</i> , 2014, 41, e58-e65.	0.6	60
10	⁴⁷ Sc as useful ”-emitter for the radiotheragnostic paradigm: a comparative study of feasible production routes. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 5.	3.9	60
11	Therapeutic Radiometals Beyond ¹⁷⁷ Lu and ⁹⁰ Y: Production and Application of Promising ”-Particle, ”-Particle, and Auger Electron Emitters. <i>Journal of Nuclear Medicine</i> , 2017, 58, 91S-96S.	5.0	58
12	Production and characterization of no-carrier-added ¹⁶¹ Tb as an alternative to the clinically-applied ¹⁷⁷ Lu for radionuclide therapy. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 12.	3.9	56
13	⁴⁴ Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 1, 8.	3.9	53
14	First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced ⁴⁴ Sc-DOTATOC: A Proof-of-Concept Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 124-132.	1.0	52
15	Radiometals for imaging and theragnostics, current production, and future perspectives. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 615-634.	1.0	49
16	Alpha-PET for Prostate Cancer: Preclinical investigation using ¹⁴⁹ Tb-PSMA-617. <i>Scientific Reports</i> , 2019, 9, 17800.	3.3	49
17	Production and separation of ⁴³ Sc for radiopharmaceutical purposes. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2017, 2, 14.	3.9	45
18	Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of ¹⁶¹ Tb-folate and ¹⁷⁷ Lu-folate. <i>EJNMMI Research</i> , 2016, 6, 13.	2.5	43

#	ARTICLE	IF	CITATIONS
19	Imaging quality of ⁴⁴ Sc in comparison with five other PET radionuclides using Derenzo phantoms and preclinical PET. <i>Applied Radiation and Isotopes</i> , 2016, 110, 129-133.	1.5	43
20	First-in-Humans Application of ¹⁶¹ Tb: A Feasibility Study Using ¹⁶¹ Tb-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1391-1397.	5.0	42
21	⁶⁴ Cu- and ⁶⁸ Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate. <i>Molecular Pharmaceutics</i> , 2016, 13, 1979-1987.	4.6	41
22	Preclinical in vivo application of ¹⁵² Tb-DOTANOC: a radiolanthanide for PET imaging. <i>EJNMMI Research</i> , 2016, 6, 35.	2.5	40
23	Preclinical investigations and first-in-human application of ¹⁵² Tb-PSMA-617 for PET/CT imaging of prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 68.	2.5	39
24	Developments toward the Implementation of ⁴⁴ Sc Production at a Medical Cyclotron. <i>Molecules</i> , 2020, 25, 4706.	3.8	38
25	A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with ⁶⁸ Ga, ⁴⁴ Sc, ¹⁷⁷ Lu and ¹⁶¹ Tb. <i>Molecules</i> , 2020, 25, 966.	3.8	36
26	Studies of the effect of tracer activity on time-averaged positron emission particle tracking measurements on tumbling mills at PEPT Cape Town. <i>Minerals Engineering</i> , 2011, 24, 261-266.	4.3	35
27	Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1113-1126.	6.4	32
28	From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 422-437.	4.6	30
29	Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for ⁶⁴ Cu-Based PET Imaging. <i>Molecular Pharmaceutics</i> , 2018, 15, 5556-5564.	4.6	28
30	Evaluation of the first ⁴⁴ Sc-labeled Affibody molecule for imaging of HER2-expressing tumors. <i>Nuclear Medicine and Biology</i> , 2017, 45, 15-21.	0.6	26
31	Positron emission particle tracking measurements with 50 micron tracers. <i>Chemical Engineering Science</i> , 2012, 75, 235-242.	3.8	25
32	Determination of ¹⁶¹ Tb half-life by three measurement methods. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109085.	1.5	25
33	Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 37.	3.9	25
34	Therapeutic Potential of ⁴⁷ Sc in Comparison to ¹⁷⁷ Lu and ⁹⁰ Y: Preclinical Investigations. <i>Pharmaceutics</i> , 2019, 11, 424.	4.5	24
35	CERN-MEDICIS: A Review Since Commissioning in 2017. <i>Frontiers in Medicine</i> , 2021, 8, 693682.	2.6	22
36	Dosimetric Analysis of the Short-Ranged Particle Emitter ¹⁶¹ Tb for Radionuclide Therapy of Metastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 2011.	3.7	19

#	ARTICLE	IF	CITATIONS
37	Cross section measurement of terbium radioisotopes for an optimized ^{155}Tb production with an 18 MeV medical PET cyclotron. <i>Applied Radiation and Isotopes</i> , 2022, 184, 110175.	1.5	18
38	The production of ^{88}Y in the proton bombardment of natSr : New excitation and separation studies. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1320-1323.	1.5	17
39	Internal radiation dosimetry of a ^{152}Tb -labeled antibody in tumor-bearing mice. <i>EJNMMI Research</i> , 2019, 9, 53.	2.5	17
40	Simultaneous Visualization of ^{161}Tb - and ^{177}Lu -Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging. <i>Pharmaceutics</i> , 2021, 13, 536.	4.5	17
41	New Radionuclides and Technological Advances in SPECT and PET Scanners. <i>Cancers</i> , 2021, 13, 6183.	3.7	16
42	Radiochemical separation of ^{88}Y from a SrCl_2 target using chelating resin Chelex 100. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2006, 270, 641-643.	1.5	14
43	Implementation of a new separation method to produce qualitatively improved ^{64}Cu . <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 460-470.	1.0	14
44	Expanding the Scope of Pyclen-Picolinate Lanthanide Chelates to Potential Theranostic Applications. <i>Inorganic Chemistry</i> , 2020, 59, 11736-11748.	4.0	14
45	^{165}Er : A new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets. <i>Applied Radiation and Isotopes</i> , 2020, 159, 109079.	1.5	14
46	In Vivo Imaging of Local Inflammation: Monitoring LPS-Induced CD80/CD86 Upregulation by PET. <i>Molecular Imaging and Biology</i> , 2021, 23, 196-207.	2.6	12
47	Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. <i>Frontiers in Medicine</i> , 2021, 8, 643175.	2.6	11
48	Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides. <i>Diagnostics</i> , 2021, 11, 1826.	2.6	10
49	The use of selective volatilization in the separation of ^{68}Ge from irradiated Ga targets. <i>Applied Radiation and Isotopes</i> , 2011, 69, 727-731.	1.5	9
50	In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs. <i>Molecular Pharmaceutics</i> , 2018, 15, 4995-5004.	4.6	9
51	Measurement of the ^{43}Sc production cross-section with a deuteron beam. <i>Applied Radiation and Isotopes</i> , 2019, 145, 205-208.	1.5	9
52	Separation of ^{103}Pd from Rh and Ag by the macroporous AG MP-1 anion exchange resin in Ag targets. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2003, 256, 31-35.	1.5	5
53	First Phantom-Based Quantitative Assessment of Scandium-44 Using a Commercial PET Device. <i>Frontiers in Physics</i> , 2020, 8, .	2.1	5
54	Activity standardisation of ^{161}Tb . <i>Applied Radiation and Isotopes</i> , 2020, 166, 109411.	1.5	5

#	ARTICLE	IF	CITATIONS
55	The Metamorphosis of Radionuclide Production and Development at Paul Scherrer Institute. <i>Chimia</i> , 2022, 74, 968.	0.6	5
56	Targeted Radiotherapeutics from 'Bench-to-Bedside'. <i>Chimia</i> , 2022, 74, 939.	0.6	5
57	Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161. <i>EJNMMI Physics</i> , 2022, 9, 19.	2.7	5
58	Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation. <i>Molecules</i> , 2022, 27, 4158.	3.8	5
59	The isolation of ^{133}Ba produced by proton-induced reactions on Cs using cation exchange chromatography. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2010, 285, 491-498.	1.5	4
60	Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute. <i>Pharmaceutics</i> , 2019, 11, 450.	4.5	4
61	Determination of the gamma and X-ray emission intensities of erbium-169. <i>Applied Radiation and Isotopes</i> , 2021, 176, 109823.	1.5	4
62	Concurrent spectrometry of annihilation radiation and characteristic gamma-rays for activity assessment of selected positron emitters. <i>Applied Radiation and Isotopes</i> , 2017, 129, 76-86.	1.5	3
63	High Efficiency Cyclotron Trap Assisted Positron Moderator. <i>Instruments</i> , 2018, 2, 10.	1.8	3
64	Determination of the gamma and X-ray emission intensities of terbium-161. <i>Applied Radiation and Isotopes</i> , 2021, 174, 109770.	1.5	3
65	Ytterbium-175 half-life determination. <i>Applied Radiation and Isotopes</i> , 2021, 176, 109893.	1.5	3
66	Production of ^{111}In from an $\text{In}/\text{In}_2\text{O}_3$ target. <i>Radiochimica Acta</i> , 2005, 93, 575-577.	1.2	1
67	Production of ^{28}Mg by bombardment of natCl with 200 MeV protons: Proof-of-concept study for a stacked LiCl target. <i>Applied Radiation and Isotopes</i> , 2016, 115, 125-132.	1.5	1
68	Non-conventional radionuclides: The pursuit for perfection. , 2022, , 133-142.		1
69	Terbium radionuclides for theranostics. , 2021, , .		0